Cover Image

Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment

Abstract Background and Objective Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world outcomes of Durva/Treme for u-HCC, with a focus on trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Yudai Fujiwara (Author), Hidekatsu Kuroda (Author), Tamami Abe (Author), Keisuke Kakisaka (Author), Ippeki Nakaya (Author), Asami Ito (Author), Takuya Watanabe (Author), Kenji Yusa (Author), Tomoaki Nagasawa (Author), Hiroki Sato (Author), Akiko Suzuki (Author), Kei Endo (Author), Yuichi Yoshida (Author), Takayoshi Oikawa (Author), Kei Sawara (Author), Akio Miyasaka (Author), Takayuki Matsumoto (Author)
Format: Book
Published: Adis, Springer Healthcare, 2024-10-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background and Objective Durvalumab plus tremelimumab (Durva/Treme) has recently been approved as a first-line or later-line treatment for patients with unresectable hepatocellular carcinoma (u-HCC) in Japan. We assessed the real-world outcomes of Durva/Treme for u-HCC, with a focus on treatment efficacy and safety. Methods We retrospectively evaluated 22 patients with u-HCC treated with Durva/Treme at Iwate Medical University during the period from 2023 to 2024, with a comparison of the clinical outcomes between patients who received Durva/Treme as first-line and later-line treatments. We further evaluated changes in the modified albumin-bilirubin (mALBI) grade during treatment. Results There were 10 patients in the first-line group and 12 patients in the later-line treatment group. During the follow-up with a median duration of 7.6 months, the median progression-free survival (first-line versus later-line: 4.7 months versus 2.9 months, p = 0.85), the objective response rate (0.0% versus 16.7%, p = 0.48), the disease control rate (60.0% versus 58.4%, p = 1.00), and the incidence of any adverse event (50.0% versus 75.0%, p = 0.38) were not statistically different between the two groups. The changes in the mALBI scores were not statistically significant (p = 0.75). Conclusions Durva/Treme may be effective and safe for patients with u-HCC, even in patients who receive Durva/Treme as a later-line treatment.
Item Description:10.1007/s40801-024-00458-7
2199-1154
2198-9788

Similar Items